1. Role of formulation vehicles in taxane pharmacology;Van Zuylen;Invest. New Drugs,2001
2. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications;Sparreboom;Cancer Res.,1999
3. Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel;Rodrigues;J. Pharm. Pharmacol.,2002
4. Phase I trial in advanced malignancies with liposome-encapsulated paclitaxel (LEP) Q 3 weeks;Bowden;Proc. Am. Soc. Clin. Oncol.,2002
5. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel;Ibrahim;Clin. Cancer Res.,2002